Bioresorbable scaffolds: everything resolved?

Bioresorbable scaffolds: everything resolved?

So, knowing the good results with DES the question is if there is still room and need for further improvement? After the introduction of the bioresorbable scaffold (BRS) and the promising results of the Absorb A and B trial, one would think that we are really missing the boat if we do not use this novel but still expensive device. The major advantage of the new scaffolds promises to overcome th...

Bioresorbable Vascular Scaffolds for Coronary Revascularization.

Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction, restenosis) after 1 year. The pathogenesis of these very late events is likely related to the permanent presence of the metal stent frame or polymer. Bioresorbable scaffolds have been developed to provide drug delivery an...

Bioresorbable Scaffolds for Cardiovascular Tissue Engineering

Cardiovascular disease is a major cause of morbidity and mortality, especially in developed countries. Currently, when suitable autologous tissue is lacking, mostly non-degradable synthetic material or fixated xenogeneic grafts (e.g. heart valves) are used to restore, repair, or replace the injured cardiovascular tissues. However, these materials are associated with several disadvantages, such ...

Bioresorbable polymeric vascular scaffolds: a cautionary tale.

The everolimus-eluting bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa Clara, CA) is an exciting advance in percutaneous coronary intervention (PCI), providing a temporary coronary scaffold for at least 3 months and being resorbed by about 2 years.1–3 Along with patient preference, potential advantages over metallic stents include restored vasomotion, reduced late thrombosis, and u...

Bioresorbable vascular scaffolds: between promises and reality